Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4
Open Access
- 1 January 2005
- journal article
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. 1 (1), 3-13
- https://doi.org/10.2147/tcrm.1.1.3.53600
Abstract
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishingKeywords
This publication has 119 references indexed in Scilit:
- Mechanism-Based Inactivation of Cytochrome P450 3A4 by L-754,394Biochemistry, 2000
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000
- ASTEMIZOLE USE WITH ERYTHROMYCINAnnals of Allergy, Asthma & Immunology, 1999
- Clinical Pharmacokinetics of MibefradilClinical Pharmacokinetics, 1998
- Inhibition and Induction of Cytochrome P450 and the Clinical ImplicationsClinical Pharmacokinetics, 1998
- RitonavirClinical Pharmacokinetics, 1998
- Clinically Significant Pharmacokinetic Drug Interactions with CarbamazepineClinical Pharmacokinetics, 1996
- Severe carbamazepine toxicity induced by concurrent erythromycin therapyEuropean Journal of Pediatrics, 1996
- P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclaturePharmacogenetics, 1996
- Validation of an asthma knowledge questionnaireJournal of Paediatrics and Child Health, 1990